



Poseida Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Aug. 29, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced that the Company will participate in fireside chats at the following upcoming investor conferences in September:

H.C. Wainwright 26th Annual Global Investment Conference

Date: Monday, September 9, 2024

Time: 10:30am ET

2024 Cantor Global Healthcare Conference

Date: Tuesday, September 17, 2024

Time: 1:20pm ET

Live webcasts of the fireside chats will be available on the Investors & Media Section of Poseida's website, www.poseida.com. A replay of the webcast will be available for approximately 90 days following the presentation.

About Poseida Therapeutics, Inc.

Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes investigational allogeneic CAR-T cell therapies for both solid tumors and hematologic cancers as well as investigational in vivo genetic medicines that address patient populations with high unmet medical need. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral piggyBac[®] DNA Delivery System, Cas-CLOVER[™] Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. The Company has formed strategic collaborations with Roche and Astellas to unlock the promise of cell therapies for cancer patients. Learn more at www.poseida.com and connect with Poseida on [X](#) and [LinkedIn](#).

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-upcoming-investor-conferences-302234400.html>

SOURCE Poseida Therapeutics, Inc.

Poseida Investor and Media Relations: Alex Chapman, Senior Vice President, IR & Corporate Communications, IR@poseida.com | Sarah Thailing, Senior Director, IR & Corporate Communications, PR@poseida.com